Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1-24 months old with symptoms of gastroesophageal reflux disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 45, Issue 5, 2007, Pages 530-537

  Omari, Taher ^a,b   Davidson, Geoffrey ^a,b   Bondarov, Patrik ^c   Nauclér, Emma ^c   Nilsson, Catarina ^c   Lundborg, Per ^c  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Esomeprazole; Gastroesophageal reflux disease; Infants; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ESOMEPRAZOLE;

AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; ESOPHAGUS PH; FEMALE; GASTRIC PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMAN; INFANT; IRRITABILITY; MALE; MORNING DOSAGE; NOSE CONGESTION; PH MEASUREMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; STOMACH ACID; SYMPTOM; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ANTI-ULCER AGENTS; AREA UNDER CURVE; AUSTRALIA; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; INFANT; INFANT, NEWBORN; OMEPRAZOLE; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME;

EID: 37349129851     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31812e012f     Document Type: Article

References (30)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
2. Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993;69:655-9.
3. Kato S, Ebina K, Fujii K, et al. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996;128:415-21.
4. De Giacomo C, Bawa P, Franceschi M, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997;24:528-32.
5. Strauss RS, Calenda KA, Dayal Y, et al. Histological esophagitis: clinical and histological response to omeprazole in children. Dig Dis Sci 1999;44:134-9.
6. Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000;137:800-7.
7. Tolia V, Ferry G, Gunasekaran T, et al. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002;35 (Suppl 4):S308-18.
8. Cezard JP. Review article: managing gastro-oesophageal reflux disease in children. Digestion 2004;69 (Suppl 1):3-8.
9. Gold BD. Epidemiology and management of gastro-oesophageal reflux in children. Aliment Pharmacol Ther 2004;19 (Suppl 1): 22-7.
10. Tolia V, Wuerth A, Thomas R. Gastroesophageal reflux disease: review of presenting symptoms, evaluation, management, and outcome in infants. Dig Dis Sci 2003;48:1723-9.
11. Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001;32 (Suppl 2):S1-31.
12. Omari TI, Barnett CP, Benninga MA, et al. Mechanisms of gastrooesophageal reflux in preterm and term infants with reflux disease. Gut 2002;51:475-9.
13. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:2616-20.
14. Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, et al. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Digestion 2003;68:184-8.
15. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40mg and rabeprazole 20mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004;60:531-9.
16. Carroccio A, Cavataio F, Acierno E, et al. Use of 24-hour oesophageal pH-metry for the detection of gastro-oesophageal reflux in infants: what is the ideal score and the optimal threshold? A receiver-operating-characteristic analysis. Ital J Gastroenterol Hepatol 1997;29:297-302.
17. Moore DJ, Tao BS, Lines DR, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003;143:219-23.
18. Strobel CT, Byrne WJ, Ament ME, et al. Correlation of esophageal lengths in children with height: application to the Tuttle test without prior esophageal manometry. J Pediatr 1979;94:81-4.
19. Zhao J, Li J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006;28:1868-76.
20. Omari TI, Haslam R, Lundborg P, et al. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007;44:41-4.
21. Orenstein SR, Shalaby TM, Cohn JF, et al. Reflux symptoms in 100 normal infants: diagnostic validity of the infant gastroesophageal reflux questionnaire. Clin Pediatr 1996;35:607-14.
22. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999;159:649-57.
23. Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:861-7.
24. Li XQ, Andersson TB, Ahlström M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7.
25. De Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999;37:485-505.
26. Treluyer J-M, Gueret G, Cheron G, et al. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics 1997;7:441-52.
27. Andersson T, Röhss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-9.
28. Condino AA, Sondheimer J, Pan Z, et al. Evaluation of infantile acid and nonacid gastroesophageal reflux using combined pH monitoring and impedance measurement. J Pediatr Gastroenterol Nutr 2006;42:16-21.
29. Alliet P, Raes M, Bruneel E, et al. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998;132:352-4.
30. Tamhankar AP, Peters JH, Portale G, et al. Omeprazole does not reduce gastroesophageal reflux: new insights using multichannel intraluminal impedance technology. J Gastrointest Surg 2004;8:890-7.